Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.55 |
| ▸ | RAF1 | P04049 | 13/20 | 0.34 |
| ▸ | BRAF | P15056 | 6/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20972064 | 0.90 | IDO1 (0.47) | IDO1CYP2C9TACR1 | |
| SCHEMBL30636537 | 0.90 | IDO1 (0.47) | IDO1CYP2C9TACR1 | |
| SCHEMBL22439174 | 0.90 | IDO1 (0.54) | IDO1CYP2C9RAF1BRAFTACR1 | |
| SCHEMBL20972220 | 0.90 | IDO1 (0.46) | IDO1CYP2C9TACR1 | |
| SCHEMBL30636541 | 0.90 | IDO1 (0.46) | IDO1CYP2C9TACR1 | |
| Potassium Ion SCHEMBL20972078 | 0.89 | IDO1 (0.53) | IDO1CYP2C9RAF1BRAFTACR1 | |
| SCHEMBL20998161 | 0.88 | IDO1 (0.49) | IDO1CYP2C9RAF1BRAF | |
| SCHEMBL20972206 | 0.88 | IDO1 (0.69) | IDO1CYP2C9RAF1BRAF | |
| SCHEMBL20972223 | 0.86 | IDO1 (0.77) | IDO1CYP2C9RAF1BRAF | |
| SCHEMBL20972260 | 0.84 | IDO1 (0.58) | IDO1CYP2C9RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111344287-B | Novel substituted biaryl compounds as indoleamine 2, 3-dioxygenase (IDO) inhibitors | 默沙东有限责任公司 | 2023-12-19 | — | — | CN | disclosed |
| EP-3710444-B1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-3710444-B1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-10995085-B2 | Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-05-04 | — | — | US | disclosed |
| US-10995085-B2 | Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-05-04 | — | — | US | disclosed |
| EP-3710444-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200216425-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200216425-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-07-09 | — | — | US | disclosed |
| CN-111344287-A | Novel substituted biaryl compounds as indoleamine 2, 3-dioxygenase (IDO) inhibitors | 默沙东公司 | 2020-06-26 | — | — | CN | disclosed |
| US-10647705-B2 | Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10647705-B2 | Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190144433-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
| US-20190144433-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647705-B2 | Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, KYNU | IDO1 1/4885CYP2C9 1054/4885RAF1 2672/4885 |
| US-20200216425-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | IDO1 1/4885CYP2C9 1406/4885RAF1 3088/4885 |
| US-10995085-B2 | Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, KYNU | IDO1 1/4885CYP2C9 1054/4885RAF1 2672/4885 |
| US-20190144433-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | IDO1 1/4885CYP2C9 1406/4885RAF1 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.